In this roundtable discussion published in Corporate Disputes, Sean Sheridan and two other panelists discuss recent trends in patent disputes. Dr. Sheridan dicusses the sharp decline in petitions for inter partes review filed at the Patent Trial and Appeal Board (PTAB) as well an an increase in the number of bills seeking to limit patent protection for pharmaceutical and biologic products.
Click the link below to download a PDF of the article.
CRA consultants named top patent professionals in the 2025 IAM Patent 1000 rankings
Fourteen CRA consultants were recognized as leading economic, financial, and licensing expert witnesses by Intellectual Asset Management (IAM). The IAM Patent...